These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 8956684)
21. Plasma reduced haloperidol/haloperidol ratios in schizophrenic patients treated with high dosages of haloperidol. Chang WH; Shieh YS; Liu HC; Jann MW; Chien CP Eur Neuropsychopharmacol; 1994 Jun; 4(2):119-26. PubMed ID: 7919941 [TBL] [Abstract][Full Text] [Related]
22. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Van Putten T; Marder SR; Mintz J; Poland RE Am J Psychiatry; 1992 Apr; 149(4):500-5. PubMed ID: 1554036 [TBL] [Abstract][Full Text] [Related]
23. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations. Davidson M; Kahn RS; Knott P; Kaminsky R; Cooper M; DuMont K; Apter S; Davis KL Arch Gen Psychiatry; 1991 Oct; 48(10):910-3. PubMed ID: 1929760 [TBL] [Abstract][Full Text] [Related]
24. An open trial of buspirone added to neuroleptics in schizophrenic patients. Goff DC; Midha KK; Brotman AW; McCormick S; Waites M; Amico ET J Clin Psychopharmacol; 1991 Jun; 11(3):193-7. PubMed ID: 2066458 [TBL] [Abstract][Full Text] [Related]
36. Low plasma reduced haloperidol/haloperidol ratios in Chinese patients. Chang WH; Chen TY; Lee CF; Hu WH; Yeh EK Biol Psychiatry; 1987 Nov; 22(11):1406-8. PubMed ID: 3663790 [No Abstract] [Full Text] [Related]
37. Treatment of chronic schizophrenia with cyproheptadine: a double-blind placebo-controlled study. Silver H; Blacker M; Weller MP; Lerer B Biol Psychiatry; 1991 Sep; 30(5):523-5. PubMed ID: 1932400 [No Abstract] [Full Text] [Related]
38. The Dose Reduction in Schizophrenia (DORIS) Study: a final report. Hirschowitz J; Hitzemann R; Piscani K; Burr G; Frecska E; Culliton D; Mann M; Curtis C Schizophr Res; 1997 Jan; 23(1):31-43. PubMed ID: 9050126 [TBL] [Abstract][Full Text] [Related]
39. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505 [TBL] [Abstract][Full Text] [Related]
40. Haloperidol blood levels and clinical outcome: a meta-analysis of studies relevant to testing the therapeutic window hypothesis. de Oliveira IR; de Sena EP; Pereira EL; Miranda AM; de Oliveira NF; Ribeiro MG; de Castro-e-Silva E; Dardennes RM; Samuel-Lajeunesse B; Marcilio C J Clin Pharm Ther; 1996 Aug; 21(4):229-36. PubMed ID: 8933296 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]